Protara Therapeutics (TARA) Research & Development (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Research & Development data on file, last reported at $13.6 million in Q1 2026.

• On a quarterly basis, Research & Development rose 48.25% year-over-year to $13.6 million in Q1 2026; TTM through Mar 2026 was $47.0 million, a 42.12% increase from a year earlier, with the FY2025 full-year figure at $42.6 million, up 34.47% from the prior year.
• Research & Development for Q1 2026 stood at $13.6 million, up from $13.1 million in the prior quarter.
• Over the last five years, Research & Development for TARA reached as high as $13.6 million in Q1 2026 and fell as low as $3.1 million in Q2 2022.
• Historically, Research & Development has averaged $7.6 million across 5 years, with a median of $7.2 million in 2023.
• Across the five-year window, Research & Development sank 47.61% in 2022 and surged 134.99% in 2023, its largest moves.
• Year by year, Research & Development stood at $5.0 million in 2022, then advanced by 27.9% to $6.4 million in 2023, then soared by 48.86% to $9.5 million in 2024, then surged by 38.16% to $13.1 million in 2025, then grew by 3.34% to $13.6 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $13.6 million in Q1 2026, $13.1 million in Q4 2025, and $9.6 million in Q3 2025.